Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Sells $84,404.25 in Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van sold 5,825 shares of Nurix Therapeutics stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $14.49, for a total transaction of $84,404.25. Following the sale, the chief financial officer now directly owns 33,724 shares of the company’s stock, valued at $488,660.76. This represents a 14.73 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Houte Hans Van also recently made the following trade(s):

• On Thursday, January 30th, Houte Hans Van sold 2,811 shares of Nurix Therapeutics stock. The shares were sold at an average price of $19.85, for a total transaction of $55,798.35.

Nurix Therapeutics Trading Up 0.5 %

Shares of NRIX stock opened at $14.26 on Wednesday. The business’s fifty day simple moving average is $18.40 and its 200-day simple moving average is $21.72. The company has a market cap of $1.08 billion, a PE ratio of -4.93 and a beta of 2.14. Nurix Therapeutics, Inc. has a 12-month low of $11.90 and a 12-month high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.08). Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. On average, equities analysts forecast that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on NRIX. JPMorgan Chase & Co. decreased their price target on shares of Nurix Therapeutics from $31.00 to $30.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. Morgan Stanley boosted their price objective on shares of Nurix Therapeutics from $16.00 to $17.00 and gave the stock an “equal weight” rating in a research note on Monday, February 3rd. Stifel Nicolaus boosted their price objective on shares of Nurix Therapeutics from $34.00 to $36.00 and gave the stock a “buy” rating in a research note on Wednesday, January 29th. Needham & Company LLC reduced their price objective on shares of Nurix Therapeutics from $29.00 to $28.00 and set a “buy” rating for the company in a research note on Wednesday, January 29th. Finally, Stephens reissued an “overweight” rating and issued a $31.00 price objective on shares of Nurix Therapeutics in a research note on Tuesday, January 21st. One analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $31.81.

Institutional Investors Weigh In On Nurix Therapeutics

A number of large investors have recently made changes to their positions in NRIX. International Assets Investment Management LLC grew its holdings in shares of Nurix Therapeutics by 1,098.4% during the third quarter. International Assets Investment Management LLC now owns 4,494 shares of the company’s stock valued at $101,000 after buying an additional 4,119 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Nurix Therapeutics by 31.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company’s stock valued at $54,000 after buying an additional 559 shares during the last quarter. Amalgamated Bank grew its holdings in shares of Nurix Therapeutics by 30.6% during the third quarter. Amalgamated Bank now owns 2,182 shares of the company’s stock valued at $49,000 after buying an additional 511 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. purchased a new stake in shares of Nurix Therapeutics during the third quarter valued at $12,432,000. Finally, Victory Capital Management Inc. purchased a new stake in shares of Nurix Therapeutics during the third quarter valued at $484,000.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.